These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 833581)

  • 1. Serum dopamine-beta-hydroxylase in parkinsonism.
    Markianos ES; Rüther E
    J Neural Transm; 1977; 40(1):21-5. PubMed ID: 833581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normal plasma dopamine-beta-hydroxylase in non-treated and treated Parkinson patients.
    Markianos M; Hadjikonstantinou M; Sfagos C
    Acta Neurol Scand; 1981 Apr; 63(4):267-72. PubMed ID: 7211191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of idiopathic parkinsonism with L-dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of L-dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa.
    Boomsma F; Meerwaldt JD; Man in't Veld AJ; Hovestadt A; Schalekamp MA
    J Neurol; 1989 May; 236(4):223-30. PubMed ID: 2760634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma dopamine beta hydroxylase (D.B.H.) activity in Parkinsonian patients under L-dopa, and 2-bromo-alpha-ergocriptine loading.
    Vardi J; Flechter S; Oberman Z; Allelov M; Rabey JM; Hertzberg M; Streifler M
    J Neural Transm; 1979; 46(1):71-8. PubMed ID: 501350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of levodopa alone and in combination with dopa-decarboxylase inhibitors on plasma renin activity in patients with Parkinson's disease.
    Rappelli A; Glorioso N; Tedde R; Dessi'-Fulgheri P; Monaco F
    J Neurol Neurosurg Psychiatry; 1978 Oct; 41(10):915-8. PubMed ID: 731241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
    Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
    Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
    Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H
    J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
    Johnson RD; Ruthven CR; Goodwin BL; Sandler M
    J Neural Transm; 1976; 38(3-4):181-91. PubMed ID: 956809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacology of Parkinson's disease: basic aspects and recent advances.
    Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE
    Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group.
    Ghika J; Gachoud JP; Gasser U
    Clin Neuropharmacol; 1997 Apr; 20(2):130-9. PubMed ID: 9099465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
    Jonkers N; Sarre S; Ebinger G; Michotte Y
    J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
    Shen H; Kannari K; Yamato H; Arai A; Matsunaga M
    Tohoku J Exp Med; 2003 Mar; 199(3):149-59. PubMed ID: 12703659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serum dopamine-beta-hydroxylase, glutamic acid decarboxylase and 1-aromatic amino acid decarboxylase in involuntary movement disorders (author's transl)].
    Nakamura S; Miyata S; Kameyama M
    Rinsho Shinkeigaku; 1979 Aug; 19(8):511-4. PubMed ID: 159153
    [No Abstract]   [Full Text] [Related]  

  • 15. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
    Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
    Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma dopamine-beta-hydroxylase and erythrocyte acetylcholinesterase in a group of patients with Parkinson disease.
    Coelho H; Azevedo M; Proença C; e Silva JM; Manso C
    J Neural Transm; 1978; 42(2):163-6. PubMed ID: 650207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic analysis of stimulation-evoked overflow of noradrenaline and dopamine beta-hydroxylase from the isolated rabbit heart. The effect of DOPA decarboxylase inhibition.
    Muscholl E; Spira FJ
    Neuroscience; 1982; 7(12):3201-11. PubMed ID: 7162634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Alachkar A; Brotchie JM; Jones OT
    Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
    Lee WY; Lee EA; Jeon MY; Kang HY; Park YG
    Exp Neurol; 2006 Jan; 197(1):215-24. PubMed ID: 16269145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.